Systemic Avastin Therapy in Age-Related Macular Degeneration

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

March 31, 2008

Conditions
Macular Degeneration
Interventions
DRUG

Bevacizumab

3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals

DRUG

Sodium Chloride

3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals

Trial Locations (1)

1030

Dept. of Ophthalmology, Rudolf Foundation Clinic, Vienna

All Listed Sponsors
lead

The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

OTHER

NCT00531024 - Systemic Avastin Therapy in Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter